×
About 20 results

Brief Guide to Current Treatments for Metastatic Lung Cancer
https://www.medscape.com/viewarticle/899504

Jul 22nd, 2018 - Hello. This is Mark Kris from Memorial Sloan Kettering in New York City, speaking today about the current flurry of information and discussion about the best treatments for lung cancers at the time of diagnosis. Today I am going to focus on patients with metastatic spread, for whom systemic therapy will be the core of their treatment program. The explosion of information and clinical trial data...

KEYNOTE-189 Establishes New Lung Cancer Standard of Care
https://www.medscape.com/viewarticle/896438

May 10th, 2018 - H. Jack West, MD: Hello. I am Jack West, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute, in Seattle. Welcome to Medscape Oncology Insights. Joining me today is Hossein Borghaei, chief of the Thoracic Medical Oncology Program at Fox Chase Cancer Center in Philadelphia. Welcome. Hossein Borghaei, DO: Thank you. West: We just attended the 2018 American Associatio...

Infection Prophylaxis, Immune Therapies Lead Practice-Changing Myeloma Research at ASH 2017
https://www.medscape.com/viewarticle/891965

Feb 5th, 2018 - Hello. I'm Vincent Rajkumar, professor of medicine at the Mayo Clinic in Rochester, Minnesota. Welcome to Medscape Oncology Insights, coming to you from the 2017 American Society of Hematology (ASH) annual meeting. Today we will be discussing some of the highlights from the myeloma sessions at the meeting. As you are well aware, there has been a dramatic amount of progress made in multiple myel...

New Acellular Pertussis Vaccine Shows Promise in Adolescents
https://www.medscape.com/viewarticle/888197

Nov 8th, 2017 - NEW YORK (Reuters Health) - A new, genetically inactivated acellular pertussis vaccine appears to be safe and immunogenic in adolescents presumed to have received their primary vaccination series in childhood, researchers from Thailand report. The immunity afforded by current acellular pertussis vaccines is short-lived, so repeated booster vaccination is recommended to maintain high levels of i...

Combination Therapies: A Tipping Point for Cancer Drug Costs?
https://www.staging.medscape.com/viewarticle/887717

Nov 8th, 2017 - Hello. My name is Leonard Saltz. I'm a medical oncologist at Memorial Sloan Kettering Cancer Center in New York. I am chair of the GI oncology group as well as chair of the hospital's pharmacy committee. This question often comes up: At what point will we reach a critical tipping point where we can't afford to provide the therapies that we want? This is becoming a problem as we start to think a...

Combination Therapies: A Tipping Point for Cancer Drug Costs?
https://www.medscape.com/viewarticle/887717

Nov 8th, 2017 - Hello. My name is Leonard Saltz. I'm a medical oncologist at Memorial Sloan Kettering Cancer Center in New York. I am chair of the GI oncology group as well as chair of the hospital's pharmacy committee. This question often comes up: At what point will we reach a critical tipping point where we can't afford to provide the therapies that we want? This is becoming a problem as we start to think a...

Pembrolizumab 1st-Line in NSCLC Also Boosts Quality of Life
https://www.staging.medscape.com/viewarticle/873079

Dec 7th, 2016 - VIENNA — More good news about using the immunotherapy pembrolizumab (Keytruda, Merck & Co) in the first-line treatment of advanced non–small cell lung cancer (NSCLC). Not only does it improve survival, new data show that it also improves quality of life (QoL) in comparision with chemotherapy. Pembrolizumab was associated with clinically meaningful improvements in health-related QoL scores as we...

Pembrolizumab 1st-Line in NSCLC Also Boosts Quality of Life
https://www.medscape.com/viewarticle/873079

Dec 7th, 2016 - VIENNA — More good news about using the immunotherapy pembrolizumab (Keytruda, Merck & Co) in the first-line treatment of advanced non–small cell lung cancer (NSCLC). Not only does it improve survival, new data show that it also improves quality of life (QoL) in comparision with chemotherapy. Pembrolizumab was associated with clinically meaningful improvements in health-related QoL scores as we...

A Patient With Endoscopic Recurrence of Crohn Disease
https://www.medscape.com/viewarticle/871581_1

Nov 10th, 2016 - Case Presentation You are caring for a 24-year-old man with a significant history of penetrating small-bowel Crohn disease. He was diagnosed at age 22 years with moderately severe Crohn disease localized to the terminal ileum via ileocolonoscopy after a 6-month history of postprandial abdominal pain and weight loss. The patient was initially treated with oral mesalamine, with no clinical benefi...

A Patient With Endoscopic Recurrence of Crohn Disease
https://www.medscape.com/viewarticle/871581

Nov 10th, 2016 - Case Presentation You are caring for a 24-year-old man with a significant history of penetrating small-bowel Crohn disease. He was diagnosed at age 22 years with moderately severe Crohn disease localized to the terminal ileum via ileocolonoscopy after a 6-month history of postprandial abdominal pain and weight loss. The patient was initially treated with oral mesalamine, with no clinical benefi...

A Patient With Endoscopic Recurrence of Crohn Disease
https://www.staging.medscape.com/viewarticle/871581

Nov 10th, 2016 - Case Presentation You are caring for a 24-year-old man with a significant history of penetrating small-bowel Crohn disease. He was diagnosed at age 22 years with moderately severe Crohn disease localized to the terminal ileum via ileocolonoscopy after a 6-month history of postprandial abdominal pain and weight loss. The patient was initially treated with oral mesalamine, with no clinical benefi...

KEYNOTE-189 Establishes New Lung Cancer Standard of Care
https://emedicine.medscape.com/viewarticle/896438

H. Jack West, MD: Hello. I am Jack West, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute, in Seattle. Welcome to Medscape Oncology Insights. Joining me today is Hossein Borghaei, chief of the Thoracic Medical Oncology Program at Fox Chase Cancer Center in Philadelphia. Welcome. Hossein Borghaei, DO: Thank you. West: We just attended the 2018 American Associatio...

A Patient With Endoscopic Recurrence of Crohn Disease
https://emedicine.medscape.com/viewarticle/871581

Case Presentation You are caring for a 24-year-old man with a significant history of penetrating small-bowel Crohn disease. He was diagnosed at age 22 years with moderately severe Crohn disease localized to the terminal ileum via ileocolonoscopy after a 6-month history of postprandial abdominal pain and weight loss. The patient was initially treated with oral mesalamine, with no clinical benefi...

Combination Therapies: A Tipping Point for Cancer Drug Costs?
https://emedicine.medscape.com/viewarticle/887717

Hello. My name is Leonard Saltz. I'm a medical oncologist at Memorial Sloan Kettering Cancer Center in New York. I am chair of the GI oncology group as well as chair of the hospital's pharmacy committee. This question often comes up: At what point will we reach a critical tipping point where we can't afford to provide the therapies that we want? This is becoming a problem as we start to think a...

Brief Guide to Current Treatments for Metastatic Lung Cancer
https://emedicine.medscape.com/viewarticle/899504

Hello. This is Mark Kris from Memorial Sloan Kettering in New York City, speaking today about the current flurry of information and discussion about the best treatments for lung cancers at the time of diagnosis. Today I am going to focus on patients with metastatic spread, for whom systemic therapy will be the core of their treatment program. The explosion of information and clinical trial data...

Hepatotoxicity of Immune Checkpoint Inhibitors: An Evolving Picture of Risk Associated With a Vital Class of Immunotherapy Agents
https://emedicine.medscape.com/viewarticle/897817

Abstract and Introduction Abstract Immune checkpoint inhibitors (ICIs) block CTLA–4, PD–1 and PD–L1, or other molecules that control antitumour activities of lymphocytes. These products are associated with a broad array of immune–related toxicities affecting a variety of organs, including the liver. ICI–associated immune–mediated hepatitis (IMH) ranges in severity between mild and life–threaten...

Pembrolizumab 1st-Line in NSCLC Also Boosts Quality of Life
https://emedicine.medscape.com/viewarticle/873079

VIENNA — More good news about using the immunotherapy pembrolizumab (Keytruda, Merck & Co) in the first-line treatment of advanced non–small cell lung cancer (NSCLC). Not only does it improve survival, new data show that it also improves quality of life (QoL) in comparision with chemotherapy. Pembrolizumab was associated with clinically meaningful improvements in health-related QoL scores as we...

Four Months of Rifampicin May Be Best Option for Latent TB
https://emedicine.medscape.com/viewarticle/923572

NEW YORK (Reuters Health) - Four months of daily rifampicin is "short, safe, and effective" and is likely the best way to achieve the ambitious goal set forth by the World Health Organization (WHO) to treat 30 million patients for latent tuberculosis infection by 2022, TB experts say in Lancet Infectious Diseases. About one quarter of the world's population has latent TB infection. Daily isonia...

PPIs Tied to Infections in Children With Normal CYP2C19 Function
https://emedicine.medscape.com/viewarticle/920974

NEW YORK (Reuters Health) - Proton pump inhibitor (PPI) therapy is associated with higher infection rates in children with normal CYP2C19 function, with infections occurring in 40% of such infants in a retrospective study. Infections were significantly less common in children who were rapid or ultrarapid CYP2C19 metabolizers, researchers found. "We believe these additional infection events, whi...

Infection Prophylaxis, Immune Therapies Lead Practice-Changing Myeloma Research at ASH 2017
https://emedicine.medscape.com/viewarticle/891965

Hello. I'm Vincent Rajkumar, professor of medicine at the Mayo Clinic in Rochester, Minnesota. Welcome to Medscape Oncology Insights, coming to you from the 2017 American Society of Hematology (ASH) annual meeting. Today we will be discussing some of the highlights from the myeloma sessions at the meeting. As you are well aware, there has been a dramatic amount of progress made in multiple myel...